Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium
August 21, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya*, or TNX-102 SL, a U.S. Food and Drug...
Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update
August 14, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya*, a U.S. Food and Drug Administration-designated...
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
July 06, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 06, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals to Present at the 2017 BIO International Convention
June 16, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 16, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals Participated in the "Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored by U.S. Department of Defense
June 15, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 15, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference
June 12, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study
May 30, 2017 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 30, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
May 24, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 24, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
May 22, 2017 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update
May 15, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 15, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...